Dernières nouvelles pour Kenvue (NYSE:KVUE) Stock

Kenvue

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Kenvue Inc

Following a strong second-quarter performance, Nordstrom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) will deliver insights into its third-quarter results Tuesday after-hours. In the second quarter, the company outperformed <a href="https://www.benzinga.com/news/earnings/24/08/40588492/nordstrom-stock-rallies-on-strong-q2-earnings-details">earnings expectations with EPS of $0.96</a>, a 35.21% beat over the consensus estimate of $0.71, driven by strategic pricing and operational efficiencies. 
What Happened: Although quarterly sales of $3.894 billion narrowly missed estimates, they represented a 3.23% year-over-year increase, with digital sales up 6.2% and notable growth in Nordstrom Rack's net sales (+8.8%).
The second quarter gross profit margin of 36.6%—a 155 basis point improvement—showcased Nordstrom's focus on full-price sales and leveraging higher volumes. However, the 8.3% increase in ending inventory relative to sales growth warrants attention as the company balances stock management in a dynamic retail landscape.
Read Also: <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge</a>
For the third quarter, analysts will likely focus on Nordstrom's ability to sustain growth across both banners, particularly Nordstrom Rack, which demonstrated robust performance in the second quarter. 
Comparable sales, which increased 1.9% in the prior quarter, could signal continued consumer resilience amid economic pressures. Margins and inventory levels will remain key indicators of operational efficiency.
Nordstrom's FY guidance of $1.75–$2.05 per share suggests confidence in its growth trajectory. With strategic momentum and a focus on profitability, third quarter results will be a critical checkpoint as the company progresses toward its 2024 objectives.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">Cassava Sciences Alzheimer&#8217;s Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies</a>
<h2 class="wp-block-heading">Is JWN A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/JWN">Nordstrom</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/JWN">Nordstrom</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, JWN has a 52-week high of $24.93 and a 52-week low of $14.65.

News

What's Going On With Nordstrom (JWN) Stock?

Walmart&#8217;s CFO, John David Rainey, recently said that if President-elect Donald Trump's proposed tariffs take effect, <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">Walmart</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will need to raise prices on certain items.
Speaking with CNBC, Rainey explained, "We never want to raise prices. Our model is everyday low prices. But there probably will be cases where prices will go up for consumers."&nbsp;
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
These proposed tariffs include a 10-20% tax on all imports and could go as high as 60-100% on products from China. Retailers like Walmart, AutoZone, Lowe's and others are already speaking out about how these potential changes could make everyday goods more expensive for customers.
The majority of goods Walmart sells are not at risk of tariffs, as about two-thirds of the items sold by Walmart are made, grown or assembled in the U.S. However, tariffs may have a major effect on the remaining one-third of imported goods. In recent years, Walmart has been expanding its supply chain by sourcing from other countries to lessen its reliance on China.
Lowe's CEO Marvin Ellison also expressed concern, saying they're talking to suppliers to understand how the tariffs might affect prices.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a>
Other companies are also taking measures to deal with the tariffs. AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) CEO Philip Daniele, for example, has recently stated that if tariffs are imposed, <a href="https://www.benzinga.com/startups/24/11/42027079/we-will-pass-those-tariff-costs-back-to-the-consumer-says-ceo-of-autozone-heres-a-look-at-other-companies-raising-prices">they will pass those costs onto the consumers</a>. Because AutoZone anticipates the impact on their margins, they even plan to hike prices before the tariffs go into effect. Similarly, Steve Madden intends to shift some of its production to Vietnam, Cambodia and Mexico to lessen its dependency on Chinese production, though price increases are still possible.
<a href="https://www.benzinga.com/news/earnings/24/10/41599361/stanley-black-decker-q3-earnings-revenue-misses-cost-savings-drive-margin-gains-narrows-2024-eps-gu">Columbia Sportswear</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) has also raised concerns, with CEO Tim Boyle mentioning that the company may also have to raise prices. The National Retail Federation also <a href="https://www.benzinga.com/news/24/11/41737933/trump-tariff-proposed-may-cost-americans-78b-in-spending-study">predicted price rises for commonplace goods</a> like apparel, shoes and furniture, warning that these tariffs essentially tax the American people. They anticipate that a $100 coat may increase by up to $21, while a $90 pair of sneakers might cost between $106 and $116.
<a href="https://www.benzinga.com/insights/analyst-ratings/24/10/41451898/what-analysts-are-saying-about-dollar-tree-stock">Dollar Tree</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), which imports many of its products from China, may have to rethink its fixed-price-point model of $1.25 per item if tariffs push costs too high. This could jeopardize the retailer&#8217;s value-focused business strategy by forcing it to either absorb the additional expense or pass it on to customers.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

COLM

DLTR

Walmart CFO Says They Don't Want To Raise Prices, But 'Prices Will Go Up For Consumers' Due To Upcoming Tariffs

Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) with a Buy and raises the price target from $36 to $45.

Price Target

Analyst Ratings

SRRK

Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $45

High-rolling investors have positioned themselves bullish on Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DDOG often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 16 options trades for Datadog. This is not a typical pattern.
The sentiment among these major traders is split, with 37% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $28,125, and 15 calls, totaling $1,025,159.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $185.0 for Datadog over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Datadog's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Datadog's substantial trades, within a strike price spectrum from $100.0 to $185.0 over the preceding 30 days.
<h3>Datadog 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732551332_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/03/25</td>
<td>$15.55</td>
<td>$13.75</td>
<td>$13.75</td>
<td>$144.00</td>
<td>$137.5K</td>
<td>100</td>
<td align="right">100</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$65.4</td>
<td>$62.95</td>
<td>$64.45</td>
<td>$100.00</td>
<td>$128.9K</td>
<td>141</td>
<td align="right">27</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$27.65</td>
<td>$26.35</td>
<td>$26.74</td>
<td>$130.00</td>
<td>$120.0K</td>
<td>6.9K</td>
<td align="right">108</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$27.55</td>
<td>$26.4</td>
<td>$26.75</td>
<td>$130.00</td>
<td>$106.7K</td>
<td>6.9K</td>
<td align="right">148</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.5</td>
<td>$27.35</td>
<td>$27.5</td>
<td>$160.00</td>
<td>$74.2K</td>
<td>677</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Datadog</h3>
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.
In light of the recent options history for Datadog, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Datadog</h3>
<ul>
<li>Currently trading with a volume of 2,695,586, the DDOG's price is up by 0.89%, now at $156.22. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Datadog</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $150.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Datadog, maintaining a target price of $148. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Datadog, maintaining a target price of $155. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Datadog with a target price of $165. 
&#x2A; An analyst from Scotiabank persists with their Sector Outperform rating on Datadog, maintaining a target price of $133. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Datadog with a target price of $150. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Datadog, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

DDOG

Spotlight on Datadog: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ETN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Eaton Corp.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 36%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $26,780, and 10, calls, for a total amount of $449,756.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $270.0 to $390.0 for Eaton Corp over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eaton Corp's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eaton Corp's significant trades, within a strike price range of $270.0 to $390.0, over the past month.
<h3>Eaton Corp Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732551327_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.0</td>
<td>$14.0</td>
<td>$14.92</td>
<td>$370.00</td>
<td>$80.4K</td>
<td>1.3K</td>
<td align="right">56</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.0</td>
<td>$18.2</td>
<td>$18.3</td>
<td>$360.00</td>
<td>$75.0K</td>
<td>604</td>
<td align="right">43</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$14.9</td>
<td>$14.0</td>
<td>$14.51</td>
<td>$370.00</td>
<td>$60.0K</td>
<td>1.3K</td>
<td align="right">543</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$14.7</td>
<td>$13.9</td>
<td>$14.56</td>
<td>$370.00</td>
<td>$45.8K</td>
<td>1.3K</td>
<td align="right">456</td>
</tr>
<tr>
<td>ETN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$112.2</td>
<td>$108.9</td>
<td>$109.94</td>
<td>$270.00</td>
<td>$43.9K</td>
<td>564</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Eaton Corp</h3>
Founded in 1911 by Joseph Eaton, the eponymous company began by selling truck axles in New Jersey. Eaton has since become an industrial powerhouse largely through acquisitions in various end markets. Eaton's portfolio can broadly be divided into two parts: its electrical and industrial businesses. Its electrical portfolio (representing around 70% of company revenue) sells components within data centers, utilities, and commercial and residential buildings, while its industrial business (30% of revenue) sells components within commercial and passenger vehicles and aircraft. Eaton receives favorable tax treatment as a domiciliary of Ireland, but it generates over half of its revenue within the US.
<h3>Eaton Corp's Current Market Status</h3>
<ul>
<li>Trading volume stands at 732,546, with ETN's price down by -0.95%, positioned at $373.81.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 66 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eaton Corp</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $385.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Eaton Corp, targeting a price of $385. 
&#x2A; Reflecting concerns, an analyst from Bernstein lowers its rating to Outperform with a new price target of $382. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Eaton Corp with a target price of $320. 
&#x2A; An analyst from UBS downgraded its action to Buy with a price target of $431. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Eaton Corp, maintaining a target price of $410. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eaton Corp with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Eaton Corp's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bullish move on FedEx. Our analysis of options history for FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $386,945, and 6 were calls, valued at $357,615.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $450.0 for FedEx during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for FedEx's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of FedEx's whale trades within a strike price range from $230.0 to $450.0 in the last 30 days. 
<h3>FedEx Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732551322_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$1.3</td>
<td>$1.15</td>
<td>$1.15</td>
<td>$290.00</td>
<td>$115.1K</td>
<td>895</td>
<td>1.0K</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$59.0</td>
<td>$58.05</td>
<td>$59.0</td>
<td>$250.00</td>
<td>$88.5K</td>
<td>739</td>
<td>25</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$149.0</td>
<td>$144.0</td>
<td>$146.35</td>
<td>$450.00</td>
<td>$73.1K</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$144.0</td>
<td>$146.0</td>
<td>$450.00</td>
<td>$73.0K</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$47.0</td>
<td>$46.0</td>
<td>$47.0</td>
<td>$270.00</td>
<td>$65.8K</td>
<td>1.3K</td>
<td>15</td>
</tr>
</tbody>
</table>

<h3>About FedEx</h3>
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
Following our analysis of the options activities associated with FedEx, we pivot to a closer look at the company's own performance.
<h3>Current Position of FedEx</h3>
<ul>
<li>Trading volume stands at 510,527, with FDX's price up by 2.58%, positioned at $307.7.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 24 days.</li>
</ul>
<h3>What Analysts Are Saying About FedEx</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $348.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on FedEx with a target price of $331. 
&#x2A; An analyst from Barclays persists with their Overweight rating on FedEx, maintaining a target price of $365. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for FedEx with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In FDX Options

Truist Securities analyst Terry Tillman maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and raises the price target from $315 to $380.

Truist Securities Maintains Buy on Salesforce, Raises Price Target to $380

WIIM

Founder Group shares are trading higher after the company announced its proposed acquisition of a majority stake in VES 1 Joint Stock Company.

Stephens &amp; Co. analyst Tim Perz maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Equal-Weight and raises the price target from $61 to $75.

BRBR

Stephens & Co. Maintains Equal-Weight on BellRing Brands, Raises Price Target to $75

TNYA

Tenaya Therapeutics shares are trading higher after the company announced it dosed its first patient with TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial at the University of California, San Francisco.

ALAR

Alarum Technologies shares are trading lower. The company reported Q3 financial results.

Raymond James analyst Josh Beck reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Strong Buy and maintains $675 price target.

Reiteration

Raymond James Reiterates Strong Buy on Meta Platforms, Maintains $675 Price Target

Pseudonymous cryptocurrency trader Jelle shared his portfolio strategy in light of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) approaching $100,000 and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42139601/solana-hits-264-record-high-as-etf-filings-regulatory-optimism-drive-market-momentum">making a new all-time high.</a>
What Happened: The trader <a href="https://x.com/CryptoJelleNL/status/1860969575220740465">took</a> to X to outline his plans for capitalizing on the uptrend of major cryptocurrencies.
Bitcoin:
Gradually reducing BTC holdings by 1% weekly, increasing to 2% weekly after Bitcoin surpasses $100,000. This ensures exposure to gains while mitigating risk as volatility rises.
<ul>
<li>Taking profits with a 10% sell-off at peak levels, followed by 2% weekly reductions.</li>
</ul>
Solana:
Entered SOL at $20, sold 10% at the all-time high break and will continue reducing the position by 2% per week. 
Ethereum:
Plans to start taking 10% profits when ETH reaches new all-time highs and reduce his position 2$ per week subsequently.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Why Bitcoin's Rally Is Stalling Below $100,000</a>
Why It Matters: Jelle emphasizes reducing risk as markets grow more volatile, capitalizing on growth opportunities, and prioritizing profitable outcomes for this cycle. 
His approach encourages other traders to adopt disciplined strategies for managing gains and minimizing potential losses.
Key advice includes funneling profits directly into savings or reinvestment to secure financial wins. &#8220;It&#8217;s time to make some money. Let's make this cycle count,&#8221; Jelle concluded.
The global cryptocurrency market surpassed $3 trillion, with Bitcoin dominance at 57.8%, according to CoinMarketCap. The top ten crypto coins over the past 30 days (highest gains) include altcoins, meme coins and blockchain based tokens.
Among the top-performing cryptocurrencies over the past 30 days are: Peanut The Squirrel (CRYPTO: PNUT), Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) and The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>).
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155010/bitcoins-bull-run-betting-on-a-125k-finish-to-2024">Bitcoin&#8217;s Bull Run: Betting On A $125K Finish To 2024</a></li>
</ul>
Image: Shutterstock

$ADA

$BTC

$DOGE

$ETH

$SAND

$SOL

$XLM

Bitcoin Below $100,000 — Veteran Trader Shares Profit-Taking Strategy

CRGO

Freightos shares are trading lower after the company reported Q3 financial results and issued Q4 revenue guidance with its midpoint below estimates.

Rumble shares are trading higher after the company announced that Dr. Disrespect will provide exclusive content to Rumble Premium and lead Rumble Gaming as an advisor.

Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed<a href="https://www.benzinga.com/news/24/09/41007173/cassava-sciences-stock-rises-on-interim-safety-review-of-simufilam-phase-3-trials"> by the market</a>.
Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock&#8217;s crash Sunday night.
What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, <a href="https://www.benzinga.com/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">sending shares significantly lower </a>to start the trading week.
The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety profile.
"Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease," the company said.
Cassava Sciences CEO Rick Barry called the results "disappointing for patients and their families."
Benzinga reached out to Cassava for comment.
Shkreli, a former hedge fund manager, predicted Monday's sharp shared decline.
"If you have $ on robinhood or interactive, short SAVA now," Shkreli <a href="https://x.com/MartinShkreli/status/1860886801617125798">tweeted </a>at 10:22 p.m. ET Sunday night.
The tweet signaled a belief that Cassava Sciences stock was set to fall. Robinhood and Interactive Brokers are among the brokers who offer 24-hour trading on select stocks, which is why they were named by Shkreli.
Shkreli was asked by several people on X if his tweet was financial advice, to which he replied yes. Shkreli also told people that waiting until Monday's opening bell at 9:30 a.m. ET would be too late to short the stock.
Cassava Sciences shares were halted at 7:25 a.m. ET with the company's update coming at 7:30 a.m. ET and shares resuming for trading at 7:55 a.m. ET.
Shares quickly fell Monday morning by over 80% after the company's update.
The post by Shkreli shouldn't come as a huge surprise since a Nov. 21 thread about a 38-page paper on Cassava by the former hedge fund manager is his pinned <a href="https://x.com/MartinShkreli/status/1859681514415607930">tweet</a>.
"I don't &#x2A;think&#x2A; it doesn't work. It is impossible for it to work," the thread says.
Shkreli said Alzheimer's Disease is a very tough market to target to begin with as 98% of the last Phase 3 trials for the disease have failed. Cassava's Phase 3 treating symptomatic patients could doom it, Shkreli predicted in the thread.
"Cassava bulls are looking for a ‘lotto ticket' return, but their chances are worse than the lotto."
Shkreli was extremely confident in his prediction, with a post <a href="https://x.com/MartinShkreli/status/1860878868028269051">listing </a>the things that he would do if the Phase 3 trial met its primary endpoint.
<ol>
<li>Delete my X account</li>
<li>Shave my head on YouTube and delete that account as well</li>
<li>Begin estrogen therapy and legally change my name to Martina</li>
<li>Move to Haiti, bringing my best friend/cat Nibbles</li>
<li>Retire from business completely</li>
</ol>
Shkreli took aim at WallSteetBets, a subreddit on Reddit Monday with a <a href="https://x.com/MartinShkreli/status/1861031460586831913">tweet </a>saying that "garbage like $SAVA" comes from the subreddit.
Read Also: <a href="https://www.benzinga.com/insights/options/24/11/41817544/looking-at-cassava-sciencess-recent-unusual-options-activity">Looking At Cassava Sciences&#8217;s Recent Unusual Options Activity</a>
Why It's Important: Shkreli said Cassava not meeting the primary endpoint would make the stock "an easy short" and shares could trade near their cash value levels of $2 to $3 per share.
The prediction from Shkreli comes after the former hedge fund manager's wild past in the pharmaceutical sector. Known as "pharma bro" to many, Shkreli previously was CEO of Retrophin and Turing Pharmaceuticals. Shkreli <a href="https://www.benzinga.com/government/21/11/23904774/wall-street-crime-and-punishment-martin-shkreli-the-self-destructive-pharma-bro">famously raised the price</a> of antiparasitic drug Daraprim from $13.50 to $750 for insurance providers after Turing acquired the drug.
Shkreli was convicted of securities fraud in 2017 and currently has<a href="https://www.benzinga.com/news/24/10/41222384/pharma-bro-martin-shkreli-loses-appeal-supreme-court-imposes-65m-fine-issues-lifetime-ban-from-pharm"> a lifetime ban</a> from the pharmaceutical sector.
Before his recent Cassava Sciences focus, the former hedge funder has been making recent headlines in <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40185861/djt-trumpcoin-allegedly-launched-by-martin-shkreli-with-barron-trumps-help-tanks-98" target="_blank" rel="noopener">the cryptocurrency sector</a>.
Benzinga reached out to Shkreli for comment and did not hear back by the time of publication.
Citron Research, known for their short reports, praised Shkreli's prediction on Cassava Sciences in a <a href="https://x.com/CitronResearch/status/1861043591369429143">tweet</a>.
"$SAVA illustrates the difficulty in shorting stocks. Has been a clear fraud for years but almost became an impossible short because of the ‘new market forces'. Nice to see some good homework by @martinshkreli added with a dose of reality to achieve real price discovery," Citron Research tweeted.
SAVA Price Action: Cassava Sciences stock is down 84.6% to $4.06 on Monday versus a previous 52-week trading range of $8.79 to $42.20, hitting new 52-week lows.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre">SEC Charges Cassava Sciences Over Manipulated Alzheimer&#8217;s Trial Data, Company And Former Execs Agree To Pay Penalty</a></li>
</ul>
Photo: Wikimedia

Health Care

Movers

Trading Ideas

SAVA

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Raymond James analyst Brian MacArthur maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Outperform and lowers the price target from $26 to $25.

GOLD

Raymond James Maintains Outperform on Barrick Gold, Lowers Price Target to $25

Schneider National, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>), a premier multimodal provider of transportation, intermodal and logistics services, announced today the company, through certain wholly owned subsidiaries, has entered into a definitive agreement to acquire Cowan Systems, LLC and affiliated entities (collectively, "Cowan Systems"), for a cash purchase price of approximately $390 million, subject to certain adjustments. The sale includes separate agreements to purchase certain real estate assets relating to Cowan Systems' business for approximately $31 million in cash.

SNDR

Schneider's Has Entered Into A Definitive Agreement To Acquire Cowan Systems And Affiliated Entities, For A Cash Purchase Price Of ~$390M

Scotiabank analyst Nicholas Yulico maintains Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) with a Sector Outperform and raises the price target from $119 to $126.

Scotiabank Maintains Sector Outperform on Federal Realty Investment, Raises Price Target to $126

Scotiabank analyst Greg McGinniss maintains Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) with a Sector Perform and raises the price target from $23 to $26.

Scotiabank Maintains Sector Perform on Kimco Realty, Raises Price Target to $26

Kenvue Inc. 2024 Q3 - Results - Earnings Call Presentation

Kenvue, Inc. (KVUE) Q3 2024 Earnings Call Transcript

FDA proposes removing oral decongestant phenylephrine from OTC meds

67 Aristocrats November Dividend Cornucopia Has 39 'Safer' And 2 Ideal Dogs

Coty: With The Makeover Now Complete, This Prospect Is A Beauty

Fidelity Value Discovery Fund Q3 2024 Review

Fidelity Select Consumer Staples Portfolio Q3 2024 Review

October Readers Tagged 25 Ideal Dividend Dogs Including 6 'Safer' Of 39 Picks

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

SA quant grades ranks 20 JPMorgan overweight consumer stock picks

AGCO

AGNC

ALRM

AMCR

AMZN

ARMK

ASND

AVGO

BASFY

CHRW

COST

COTY

CVNA

CYBR

DAWN

DELL

DKNG

ESEA

EWTX

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FSMD

FSTA

FTEC

FUTY

FVAL

GWRE

HRZN

INTC

IPAR

ISRG

KLAC

KVUE

LEGN

MNDY

MSEX

MSFT

NTRA

ONEQ

OXLC

PARXF

PODD

PSEC

ROIV

RVMD

SCHW

SHEL

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TRMD

TROW

TVTX

ULTA

VICI

XENE

Press Releases

Kenvue Reports Second Quarter 2024 Results

Kenvue Introduces Patented Micro-Peptide Technology with Neutrogena® Collagen Bank™ Launch

Kenvue Announces Participation in the Barclays Global Consumer Staples Conference

Kenvue Drives Climate Action Strategy Forward

Kenvue Declares Quarterly Cash Dividend

Kenvue to Announce Third Quarter 2024 Results on November 7, 2024

Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit

Neutrogena® Launches Breakthrough Collaboration with Two of World's Most Recognizable Dermatologists

Kenvue Reports Third Quarter 2024 Results

Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

Comments

Kenvue

Actualités

Dernières nouvelles pour Kenvue (NYSE:KVUE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL